Cart
sales@molnova.com
CAN-508
CAS No. 140651-18-9
CAN-508( CAN508 )
Catalog No. M11707 CAS No. 140651-18-9
CAN-508 is a potent, selective CDK9 inhibitor with IC50 of 0.35 uM (CDK9/cyclin T1), displays >35 fold selectivity over CDK1/2/4/7 (IC50=13.5-70 uM).
CAN-508 is a potent, selective CDK9 inhibitor with IC50 of 0.35 uM (CDK9/cyclin T1), displays >35 fold selectivity over CDK1/2/4/7 (IC50=13.5-70 uM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 65 | Get Quote |
|
| 10MG | 124 | Get Quote |
|
| 25MG | 210 | Get Quote |
|
| 50MG | 311 | Get Quote |
|
| 100MG | 462 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCAN-508
-
NoteResearch use only, not for human use.
-
Brief DescriptionCAN-508 is a potent, selective CDK9 inhibitor with IC50 of 0.35 uM (CDK9/cyclin T1), displays >35 fold selectivity over CDK1/2/4/7 (IC50=13.5-70 uM).
-
DescriptionCAN-508 is a potent, selective CDK9 inhibitor with IC50 of 0.35 uM (CDK9/cyclin T1), displays >35 fold selectivity over CDK1/2/4/7 (IC50=13.5-70 uM); reduces the frequency of S-phase cells of the cancer cell line HT-29 in antiproliferation assays; decreases phosphorylation of the retinoblastoma protein and the C-terminal domain of RNA polymerase II, inhibits mRNA synthesis, and induces the tumor suppressor protein p53.
-
In VitroCAN508 reduces the frequency of S-phase cells of the cancer cell line HT-29 in antiproliferation assays.CAN508 (20-40 μM; 72 hours) significantly reduces cell proliferation in a dose dependent manner in all three esophageal adenocarcinoma cell lines (SKGT4, OE33 and FLO-1 cells) with IC50s ranging from 34.99 to 91.09 μM.CAN508 (40 μM; 72 hours) increases apoptosis in all three esophageal adenocarcinoma cells. Apoptosis Analysis Cell Line:SKGT4, OE33 and FLO-1 cells Concentration:40 μM Incubation Time:72 hours Result:Increased apoptosis by 2 fold in all three esophageal adenocarcinoma cells compared to untreated controls.
-
In VivoCAN508 (60 mg/kg; i.p.; daily for 10 days) has antitumor effects in esophageal adenocarcinoma xenografts. Animal Model:4 weeks-old female nude mice (esophageal adenocarcinoma xenografts)Dosage:60 mg/kg Administration:I.p.; daily for 10 days Result:Caused reduction of tumor growth starting from post-treatment day three with 50.83% reduction.
-
SynonymsCAN508
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number140651-18-9
-
Formula Weight218.22
-
Molecular FormulaC9H10N6O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (1145.63 mM)
-
SMILESOC1=CC=C(/N=N/C2=C(N)NN=C2N)C=C1
-
Chemical Name4-[(3,5-diamino-1H-pyrazol-4-yl)azo]-phenol
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Krystof V, et al. J Med Chem. 2006 Nov 2;49(22):6500-9.
2. Kry?tof V, et al. Eur J Med Chem. 2011 Sep;46(9):4289-94.
3. Tong Z, et al. Oncotarget. 2017 Apr 25;8(17):28696-28710.
molnova catalog
related products
-
Cucurbitacin E
Cucurbitacin E is a natural compound which from the climbing stem of Cucumic melo L. Cucurbitacin E significantly suppresses the activity of the cyclin B1/CDC2 complex.
-
CDK2 inhibitor 73
A potent, selective CDK2 inhibitor with IC50 of 44 nM for CDK2/cyclin A, displays 2,000-fold selectivity over CDK1/cyclin B (IC50=86 uM).
-
JNJ-7706621
A dual CDK/Aurora kinase inhibitor with IC50 of 9/4/11/15 nM for CDK1/CDK2/Aurora A/Aurora B respectively; also exhibits activity towards CDK3, CDK4, and CDK6 (IC50s=50-250 nM).
